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TCT-1
Left atrial dysfunction assessed with strain is related to long-term adverse events
in an elderly patients after acute coronary syndrome with percutaneous coronary
intervention
Ae-Young Her1, Yong Hoon Kim1
1Kangwon National University, Chuncheon, Gangwondo
Background: Although larger left atrial (LA) volume is known as a powerful pre-
dictor of adverse events in patients after acute myocardial infarction (MI), elderly
patients have larger LA volume in a general way. This study aimed to evaluate the
relationship between LA volume, dysfunction using strain and long-term adverse
events in an elderly patients after acute coronary syndrome (ACS).
Methods: Consecutive elderly patients admitted with ACS treated with percutaneous
coronary intervention (PCI) were evaluated. LA volume and strain (longitudinal
global strain) were quantiﬁed within 48 h of admission. The clinical endpoint was a
composite of all-cause mortality, MI, stroke and hospitalization for heart failure (HF).
Results: 225 patients (mean age, 73.811 years, 51.1% males) were followed up for
3013 months. During follow-up, 44 adverse events (19.5%) developed ; 19 all-cause
deaths, 4 MIs, 7 strokes and 14 hospitalizations for HF. After adjusting clinical and
echocardiographic parameters, LA volume (adjusted HR 1.02, 95% CI 0.96-1.09, p ¼
0.034) and LA strain (adjusted HR 1.20, 95% CI 1.01-1.41, p ¼ 0.015) independently
predicted the occurrence of the composite endpoint (Table 1). In addition, LA strain
increased the predictive power to LA volume (p ¼ 0.04) for the prediction of adverse
events in an elderly patients after ACS.Table 1. Predictors of composite endpoint (all-cause mortality, MI, stroke and
hospitalization for HF) by multivariate Cox regression analysis
Variable Adjusted HR 95% CI p Value
LA longitudinal global strain (%) 1.20 1.01-1.41 0.015
LA volume (ml/m2) 1.02 0.96-1.09 0.034
LV ejection fraction (%) 1.01 0.94-1.09 0.688
ST elevation MI 3.01 0.27-33.13 0.368
E/E’ ratio 0.93 0.78-1.10 0.373
MI, myocardial infarction; HF, heart failure; HR, hazard ratio; CI, conﬁdence interval; LA, left
atrial; LV, left ventricular.Conclusions: LA dysfunction assessed with LA strain provides additional value to LA
volume for the prediction of adverse events in an elderly patients after ACS with PCI.
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Background: The ECG is central to the triage of patients with suspected acute cor-
onary syndromes (ACS) but its accuracy in detecting coronary artery occlusion is
limited. We sought to determine the incidence, distribution and outcomes of totally
occluded culprit arteries among non-ST-segment elevation ACS (NSTEACS) patients.
Methods: The ACUITY trial was a randomized trial that enrolled 13,819 patients pre-
senting with NSTEACS undergoing early invasive strategy. We excluded patients with
multi-vessel disease and prior CABG. We compared baseline features and outcomes in
patients with an occluded (baseline TIMI 0-1) vs patent (TIMI 2-3 ﬂow) culprit vessel.
Results: Of 2,406 ACUITY patients who met study criteria, 328 (13.6%) had TIMI 0-
1 ﬂow in the culprit artery, and the RCA and LCX were more frequently occluded
than the LAD (Figure). Patients with totally occluded culprit arteries were less likely
to have hypertension and hyperlipidemia, and were more likely to have baseline ST
deviation >1mm (36.9% vs 22.8%, p < 0.0001) and biomarker elevation (82.6% vs
55.1% p < 0.0001). 1-year outcomes, including death (10.4% vs. 10.5%, p¼0.89) and
myocardial infarction (7.9% vs. 9.1%, p¼0.44), did not differ signiﬁcantly betweenJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Acpatients with vs. without occluded culprit arteries. Results were consistent after
sensitivity analysis for patients with biomarker elevation.Conclusions: The culprit artery is occluded in w1/7 patients presenting with
NSTEACS and single-vessel disease. The presence of total occlusion was not asso-
ciated with an incremental hazard of mortality or MI at 1 year.
TCT-3
A randomized comparison of drug-eluting vs. bare metal stenting in patients
with non-ST elevation myocardial infarction. Results of the ELISA-3
angiographic substudy
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Salem H. The4, Harry Suryapranata5, Arnoud van ’t Hof1
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Background: Many studies have evaluated the safety and efﬁcacy of drug-eluting
stents (DES) in patients with ST elevation myocardial infarction (STEMI), however,
randomized data in patients with Non-STEMI are scarce. In addition, few studies have
compared the newer, second generation DES stents versus a cobalt chromium bare
metal stent (BMS).
Methods: Patients with Non-STEMI included in the Early or Late Intervention in
unStable Angina 3 (ELISA-3) trial or patients with Non-STEMI who did not meet the
criteria for inclusion in ELISA-3 (RELI (¼Registration ELISA) patients) during the
study period who underwent percutaneous coronary intervention (PCI) were ran-
domized to an everolimus coated DES (Xience V) or a cobalt chromium BMS
(Vision). Primary endpoint of the ELISA-3 angiographic substudy was the incidence
of restenosis, deﬁned as a diameter stenosis of more than 50% at 9 month follow-up
angiography, as assessed by an independent core-lab. The incidence of MACE and
stent thrombosis at 2 years follow-up was the key secondary and safety endpoint
respectively in the combined ELISA-3 and RELI patients.
Results: During the study period, 474 patients (178 ELISA-3, 296 RELI) were ran-
domized (234 DES and 240 BMS). Baseline clinical and angiographic characteristics
were comparable between the groups. Nine-month follow-up angiography was per-
formed in 119 (67%) of the ELISA-3 patients. Restenosis occurred in 1.9% in the DES
group vs. 16.7% in the BMS group (RR 0.11, 95% CI 0.02-0.84, p¼ 0.007). The
incidence of MACE (12.3% (DES) vs. 15.8% (BMS), p¼0.323) or stent thrombosis
(1.6% (DES) vs. 3.6% (BMS), p¼0.339) in the combined study group did not differ
signiﬁcantly between the groups at 2 years follow-up.
Conclusions: The use of an everolimus eluting second generation drug-eluting stent in
patients with Non-STEMI is safe and decreases restenosis as compared to a cobalt
chromium bare-metal stent.
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Background: We assess clinical factors and decisions beyond the Global Registry of
Acute Coronary Events (GRACE) risk score that inﬂuence timing of revascularizationute Coronary Syndromes (non STEMI) B1
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comand subsequent impact on adverse events during Non-ST elevation myocardial
infarction (NSTEMI).
Methods: A total of 1,264 NSTEMI patients underwent PCI between 2009-2013.
GRACE scores were calculated post-hoc to assess high-risk (HR) vs. non high-risk
(non-HR) patients, and further analyzed according to revascularization time [early
revascularization (ER) 24 hrs or delayed (DR) >24 hrs]. To assess predictors of ER,
multivariate logistic models were constructed which included patient characteristics
upon presentation and GRACE score. Multivariate models were also created for effect
of ER on 6-month target vessel revascularization or major adverse cardiovascular
events (TVR-MACE) comprised of all-cause death or Q-wave MI.
Results: The majority (61%) of non-HR patients underwent ER, whereas the majority
(58%) of HR patients underwent DR. HR GRACE patients were 49% less likely to
undergo ER compared with non-HR (odds ratio [OR] 0.51, 95% CI 0.36-0.71; p <
0.001), despite their increased risk. Hemoglobin < 10g/dL (OR 0.33 [0.2-0.52] p <
0.001) and presentation year  2012 (OR 0.65 [0.5-0.86] p < 0.01) were also
associated with DR while magnitude of troponin change from baseline was associated
with ER (OR 1.02 [1.01-1.03] p ¼0.001). TVR-MACE at 6 months was signiﬁcantly
greater for HR than non-HR patients (34.9% vs. 11.4%, p < 0.001). However, E PCI
did not reduce events within either group; HR-delayed vs. early (35.1% vs. 34.6%,
hazard radio (HR) 1.10 [CI 0.64-1.88] p¼0.7) or non-HR delayed vs. early (10.2% vs.
12.1%, HR 1.73 [0.92-3.28] p ¼0.9).
Conclusions: Non-HR patients were more likely to receive ER than any other group,
possibly a result of lower procedural risk compared with HR patients and/or less
confounding associated conditions warranting attention prior to revascularization. A
clinician’s clinical gestalt appears to determine the most appropriate timing of
revascularization for patients with NSTEMI, unrelated to overall risk. This decision
does not translate into a difference in adverse events.
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Risk Versus Beneﬁt of Early Invasive Approach in Patients with Acute Coronary
Syndrome and Baseline Anemia: Analysis from the Acute Coronary Syndrome
Israeli Survey (ACSIS)
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Ilan Goldenberg4, Doron Sudarsky5
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Background: Early invasive approach (early coronary angiography [CAG] with
subsequent revascularization when necessary) is advocated in moderate- to high-risk
patients (pts) with acute coronary syndrome (ACS) to guide management. However,
whether beneﬁt of early invasive strategy exceeds the risk of bleeding in pts with ACS
and baseline anemia is not known. We therefore assessed impact of early CAG on
outcomes of pts with ACS and baseline anemia in the biennial Israeli ACS registry.
Methods: The study is based on the cumulative data from 3 consecutive surveys
conducted during 2006, 2008 and 2010. Rates of TIMI major bleeding, 30-day MACE
and 1-year mortality were analyzed.
Results: Among a total of 5600 pts with ACS, anemia at baseline was present in 1464
pts (26.1%). Early CAG was performed in 4877 pts (87.1%), including 1122 pts
(76.6%) with baseline anemia and 3755 pts (90.8%) without baseline anemia (p<
0.001). Non-performance of CAG was associated with older age, higher prevalence of
comorbidities and higher GRACE risk score. Among pts with anemia in whom CAG
was performed, the majority of pts (1071; 95.5%) had obstructive CAD of whom
73.1% were triaged to PCI, 22.2% were treated medically, and 4.7% were referred for
CABG. Clinical outcomes are presented in the Table. After adjustment for potential
covariates, performance of early CAG was associated with lower 1-year mortality (HR
[95% CI]¼0.43 [0.31-0.60], p< 0.001) without increase in major bleeding (OR [95%
CI]¼1.29 [0.55, 3.05], p¼0.55).
Conclusions: In the non-selected patients with ACS, anemia at baseline was present in
every 4th patient. Pts with ACS and baseline anemia were less likely to be managed
with early invasive approach. Despite the presence of baseline anemia, early coronary
angiography with subsequent revascularization when appropriate was associated with
improved 30-day and 1-year survival without an increase in rates of major bleeding.Outcomes,
n (%)
Patients with ACS and baseline anemia
n ¼ 1,464
P value
Coronary angiogram (+)
n ¼ 1,122
Coronary angiogram (-)
n ¼ 342
At 30 days
Death 64 (5.7) 53 (15.6) <0.0001
Reinfarction 41 (3.7) 10 (2.9%) 0.52
Stroke 6 (0.5) 4 (1.2) 0.21
Major bleeding 35 (3.1) 13 (3.8) 0.54
MACE* 99 (8.8) 62 (18.1) <0.0001
At 1 year
Death 133 (11.9) 116 (34.1) <0.0001
*Death, reinfarction or stroke
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Positive T-wave Amplitude In Lead AVR As A Predictor For A Higher Rate Of
In-hospital Coronary Artery Bypass Graft In Patients With Non-ST Elevation
Myocardial Infarction
Akihiro Kobayashi1, Naoki Misumida1, Yumiko Kanei1
1Mount Sinai Beth Israel Medical Center, New York, NY
Background: Positive T-wave amplitude in lead aVR has been shown to be associ-
ated with the presence of multi-vessel disease and worse clinical outcome in patients
with ST elevation myocardial infarction, although its effects on patients with non-ST
elevation myocardial infarction (NSTEMI) has not been fully explored. We aimed to
investigate the impact of positive T-wave amplitude in lead aVR on clinical outcomes
in NSTEMI patients.
Methods: 340 NSTEMI patients who presented during 2013 were retrospectively
reviewed. Electrocardiograms were interpreted in a blinded fashion; Positive T-wave
(PTw) was deﬁned as T-wave amplitude > 0 mV and Negative T-wave (NTw) was
deﬁned as T-wave amplitude & 0 mV in lead aVR. Patients were divided into two
groups; PTw and NTw. Angiograms were reviewed in a blinded fashion. Multi-ter-
ritorial ischemia was diagnosed based on the clinical and angiographic ﬁndings when
there is greater than 90% stenosis in more than two coronary arteries. The rate of in-
hospital revascularization procedures including percutaneous coronary intervention
(PCI) and coronary artery bypass graft (CABG) as well as in-hospital major adverse
cardiac event (MACE) including death, recurrent myocardial infarction, target vessel
revascularization, and lethal ventricular arrhythmias were compared between the two
groups.
Results: Among 340 patients, 67 patients (19.7%) had PTw and 273 (80.3%) had
NTw. Patients with PTw were more likely to have diabetes mellitus (49.2% vs. 32.6%,
p¼0.001) and hypertension (88.1 % vs. 71.8%, p¼0.006). Though there was no
signiﬁcant difference in the rate of multi-vessel disease between the two groups,
patients with PTw had a higher rate of multi-territorial ischemia (31.3% vs. 15.4%, p¼
0.003) compared to patients with NTw. The presence of PTw was associated with a
higher rate of in-hospital CABG (13.4% vs. 5.9%, p¼ 0.033) and a lower rate of in-
hospital PCI (32.8% vs. 55.3%, p¼0.001). There was no statistical difference between
the two groups in the rate of in-hospital MACE (1.5% vs. 2.2%, p¼ 0.716).
Conclusions: Positive T-wave amplitude in lead aVR was signiﬁcantly associated
with a higher rate of multi-territorial ischemia and in-hospital CABG in patients with
NSTEMI.
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Prolonged QTc Interval as a Predictor of In-hospital Heart Failure in Patients
with Non-ST Elevation Myocardial Infarction
Naoki Misumida1, Akihiro Kobayashi1, Yumiko Kanei1
1Mount Sinai Beth Israel Medical Center, New York, NY
Background: Prolonged QTc interval has been shown to have a predictive value for
major adverse cardiac event including death, recurrent ischemia, and urgent coronary
revascularization in non-ST elevation acute coronary syndrome. However, little is
known about the correlation between prolonged QTc interval and the incidence of
heart failure.
Methods: We retrospectively reviewed 292 consecutive NSTEMI patients who pre-
sented with chest pain and underwent coronary angiography within ﬁve days after
presentation from January 2013 to December 2013. Of the 292 patients, 19 patients
with atrial ﬁbrillation or paced rhythm were excluded. Electrocardiography and cor-
onary angiography were reviewed by a blind fashion. QTc prolongation was deﬁned
as QTc greater than 450ms in men and 470ms in women. The rate of in-hospital
percutaneous or surgical revascularization and in-hospital major adverse cardiac event
(MACE) including death, recurrent myocardial infarction, target vessel revasculari-
zation, lethal ventricular arrhythmias and heart failure deﬁned by Killip classS2, were
recorded. Clinical characteristics alongside electrocardiographic and angiographic
ﬁndings were compared between the patients with and without prolonged QTc
interval.
Results: Among 273 patients, 93 patients (34.1%) had prolonged QTc interval. Pa-
tients with prolonged QTc interval were more likely to have hypertension and prior
myocardial infarction than those with normal QTc interval. Patients with prolonged
QTc interval had a higher rate of in-hospital MACE (21.5% vs. 5.0%, p< 0.001),
driven by four-fold increase of heart failure (19.4% vs. 3.9%, p< 0.001). However,
there was no signiﬁcant difference in the rate of percutaneous or surgical revascu-
larization or impaired coronary blood ﬂow between the two groups. The association
between prolonged QTc interval and in-hospital heart failure persisted after adjusting
for hypertension and prior myocardial infarction (odds ratio 5.81; 95% conﬁdence
interval, 2.36 to 15.8; P< 0.001).
Conclusions: Prolonged QTc interval was commonly observed in patients with
NSTEMI, and was an independent predictor of in-hospital heart failure.3–17, 2014 j TCT Abstracts/Acute Coronary Syndromes (non STEMI)
